Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $865,000 Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 1.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 50,466 shares of the biotechnology company’s stock after buying an additional 645 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in ADMA Biologics were worth $865,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Teacher Retirement System of Texas increased its position in shares of ADMA Biologics by 25.0% in the fourth quarter. Teacher Retirement System of Texas now owns 69,044 shares of the biotechnology company’s stock worth $1,184,000 after purchasing an additional 13,811 shares during the period. Maryland State Retirement & Pension System grew its stake in ADMA Biologics by 1.1% during the fourth quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company’s stock worth $1,365,000 after buying an additional 897 shares in the last quarter. Intech Investment Management LLC increased its holdings in ADMA Biologics by 78.3% in the 4th quarter. Intech Investment Management LLC now owns 110,756 shares of the biotechnology company’s stock valued at $1,899,000 after buying an additional 48,636 shares during the period. Cibc World Markets Corp acquired a new position in shares of ADMA Biologics in the 4th quarter valued at approximately $361,000. Finally, Royce & Associates LP bought a new stake in shares of ADMA Biologics during the 4th quarter worth approximately $7,213,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Trading Down 2.6 %

ADMA opened at $19.70 on Thursday. The company’s 50 day moving average is $16.97 and its 200-day moving average is $18.11. The company has a market cap of $4.66 billion, a P/E ratio of 70.36 and a beta of 0.60. ADMA Biologics, Inc. has a 1-year low of $5.90 and a 1-year high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.